TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05844410
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
Study: NCT05697809
Drug: Ozurdex® Ophthalmic Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic dexamethasone intravitreal implant
Study: NCT05767723
Drug: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
Study: NCT05355597
Drug: Exparel Injectable Product
Normalized name: Exparel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Study: NCT05355597
Drug: Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Study: NCT06272409
Drug: DEP114
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEP114 oral solution
Study: NCT05265325
Drug: AND017 capsules TIW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
Study: NCT05265325
Drug: AND017 capsules QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
Study: NCT06228326
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC chemotherapy
Study: NCT06387147
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
Study: NCT06387147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
Study: NCT05815485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
Study: NCT05273619
Drug: XC8, film-coated tablets, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day: 4 tablets (40 mg) twice a day
Study: NCT05273619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets twice a day
Study: NCT05444699
Drug: Prednisolone Sodium Phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension administered 1 mg/kg once a day for three days
Study: NCT05350501
Drug: EO2040
Approvals — FDA: no, EMA: no, PMDA: no
Description: EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC.
Study: NCT06066437
Drug: Arm A: 177Lu rhPSMA-10.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 177Lu rhPSMA-10.1 alone.
Study: NCT05867303
Drug: RC198 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
Study: NCT06555497
Drug: topical 1% methotrexate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 1% methotrexate gel
Study: NCT05773183
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
Study: NCT04026464
Drug: Intravenous Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
Study: NCT04026464
Drug: Intravenous Ibuprofen + Oral Acetaminophen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
Study: NCT06346392
Drug: AZD0901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
Study: NCT06346392
Drug: AZD0901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV
Study: NCT06157918
Drug: SYHA1813 oral solution (2.0g:25mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1813 oral solution, 25mg, oral
Study: NCT06157918
Drug: SYHA1813 oral solution (20ml:200mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1813 oral solution, 25mg, oral
Study: NCT06558513
Drug: XNW5004 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Study: NCT05521698
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06480383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet, taken once daily, sublingual administration
Study: NCT05823532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
Study: NCT06154863
Drug: RAI
Normalized name: PRAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioactive iodine
Study: NCT05795491
Drug: Azole Antifungal
Normalized name: Azole antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
Study: NCT05121441
Drug: ARD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, oral administration
Study: NCT05121441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, oral administration
Study: NCT05718609
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT04835480
Drug: OrsHSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
Study: NCT02703610
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
Study: NCT01890941
Drug: KCT-0809 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01890941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05763693
Drug: Azithromycin at Baseline
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
Study: NCT05763693
Drug: Azithromycin at Day 21
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
Study: NCT05112328
Drug: Exocrine Pancreatic Enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
Study: NCT05112328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
Study: NCT06584916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05822518
Drug: Dipeptiven solution (Fresenius Kabi pharmaceutical)
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
Study: NCT05049616
Drug: ACE Inhibitors and Diuretics
Normalized name: ACE inhibitors and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hctz/Lisinopril (brand name: Zestoretic)
Study: NCT06036823
Drug: Dextrose 50
Normalized name: DEXTROSE 50% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: to be given to both arms
Study: NCT05241535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05147051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
Study: NCT05070195
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028, capsule, oral
Study: NCT05101785
Drug: Lidocain hydrochloride 2 % with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia infilteration in children
Study: NCT05101785
Drug: Articaine chloride 4% with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine chloride 4% with epinephrine
Study: NCT06025825
Drug: Articaine Hydrochloride + Epinephrine
Normalized name: articaine hydrochloride / epinephrine Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction.
Study: NCT06025825
Drug: Lidocaine Hydrochloride + Epinephrine
Normalized name: epinephrine / lidocaine hydrochloride Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
Study: NCT04245566
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
Study: NCT05951023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule manufactured to match encapsulated Eszopiclone
Study: NCT05901428
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Study: NCT06120127
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX/FOLFOX/FOLFIRI
Study: NCT05088356
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg/kg
Study: NCT05373277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo twice daily for two days
Study: NCT05373277
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet, single dose
Study: NCT04239859
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet up to 15mg per week
Study: NCT04908566
Drug: PD-1 antibody combined with SOX program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles.
Study: NCT05232071
Drug: IVA337
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg
Study: NCT05232071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT06433453
Drug: Indomethacin 50 MG
Normalized name: indomethacin 50 MG
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
Study: NCT05497323
Drug: Combination Cream
Normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
Study: NCT04982146
Drug: Bromelin
Normalized name: Bromelin specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg per mL of total tumor volume calculated, administered percutaneously
Study: NCT04875169
Drug: Core Treatment Active Experimental: SHR0302 Dose#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Study: NCT04875169
Drug: Core Treatment Active Experimental: SHR0302 Dose#2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Study: NCT04875169
Drug: Core Treatment Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
Study: NCT04875169
Drug: Extension Treatment Active Experimental: SHR0302 Dose#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Study: NCT04875169
Drug: Extension Treatment Active Experimental: SHR0302 Dose#2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Study: NCT04842487
Drug: R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
Study: NCT05882357
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination granules for oral administration.
Study: NCT06412224
Drug: RRG001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subretinal injection. Dosage form: injection.
Study: NCT05890950
Drug: K-757 and K-833
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally
Study: NCT05890950
Drug: Matching placebo to K-757 and K-833
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally
Study: NCT06473948
Drug: JMKX001899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JMKX001899 500mg tablet, orally once on Day 1
Study: NCT06473948
Drug: JMKX001899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JMKX001899 750mg tablet, orally once on Day 1
Study: NCT06473948
Drug: JMKX001899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
Study: NCT06473948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
Study: NCT06197490
Drug: Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
Study: NCT06054932
Drug: LK101 injection
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#LK101
Approvals — FDA: no, EMA: no, PMDA: no
Description: LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
Study: NCT06054932
Drug: LK101 injection
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#LK101
Approvals — FDA: no, EMA: no, PMDA: no
Description: LK101 administrated QW as the prime dose, and Q3W in the boost phase
Study: NCT04780399
Drug: Yangxue Qingnao pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Study: NCT04780399
Drug: Yangxue Qingnao pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Study: NCT04780399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
Study: NCT05401357
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
Study: NCT04956419
Drug: SHR8008 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 2 days(Day 1 and Day 2),oral
Study: NCT02368613
Drug: DW-3102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06252623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline will be used as the placebo and administered subcutaneously once a week for 6 weeks.
Study: NCT00347503
Drug: ketorolac 0.4%, bromfenac 0.09%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05108623
Drug: agenT-797
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study: NCT05587088
Drug: Petiveria Alliacea Preparation
Normalized name: Petiveria alliacea preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petiveria Alliacea Preparation in pill
Study: NCT05095064
Drug: Onivyde® + 5-FULV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
Study: NCT05166330
Drug: Ketofol 1:3 ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
Study: NCT06169046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT06016465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo pills
Study: NCT05570292
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
Study: NCT06254612
Drug: SP-624
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration of two capsules totaling 20 mg/day
Study: NCT06254612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration of two matching placebo capsules
Study: NCT04925661
Drug: HEC53856
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either dose of HEC53856 will be administered after fasting .
Study: NCT04925661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either dose of placebo will be administered after fasting .
Study: NCT03743194
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
Study: NCT03743194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to standard analgesia technique will be given pain medications.
Study: NCT05198804
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 will be administered.
Study: NCT02124226
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 mg/week + folic acid the day after
Study: NCT02124226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT04049851
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
Study: NCT06295302
Drug: HWH486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HWH486 capsule was administrated orally
Study: NCT06295302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was administrated orally